Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction

By LabMedica International staff writers
Posted on 03 Sep 2026

Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. More...

It accounts for about 2% of suspected heart attacks and up to one in ten women presenting with acute coronary syndrome, yet definitive diagnosis typically relies on invasive catheterization. Rapid, accurate differentiation from true infarction remains an unmet diagnostic need. New findings demonstrate a biomarker-based diagnostic score that aims to identify Takotsubo syndrome before catheterization.

Researchers at the University of Zurich, working with international collaborators, developed and validated the biomarker-based BioTAK score to support pre-catheterization diagnosis. The tool combines multiple blood biomarkers with biological sex to estimate the likelihood of Takotsubo syndrome. Artificial intelligence was used to select the most informative marker combination and convert it into a diagnostic decision aid.

In an independent validation cohort of nearly 1,800 additional patients, BioTAK identified Takotsubo syndrome with high accuracy. Predefined thresholds correctly classified nearly 90% of participants before cardiac catheterization. The score is presented as an adjunct to the initial emergency assessment rather than a replacement for invasive testing when clinically indicated.

The study also points to disease mechanisms distinct from classic myocardial infarction. Two novel biomarkers incorporated into BioTAK implicate the brain-heart axis and pathways that are independent of atherosclerosis. One protein activates neuropeptides governing stress responses, anxiety, vascular tone, and autonomic function, while the other is associated with the stability of atherosclerotic plaques.

The work, conducted in close collaboration between the University of Zurich and the University of Greifswald, was published in the European Heart Journal on August 31, 2026. Affiliations named in the announcement include the University of Oxford, University Hospital Zurich, Imperial College London, and the University Medical Center Greifswald, alongside the InterTAK Registry. Future studies will assess whether integrating BioTAK into routine practice can further improve diagnosis and treatment.

“Our study shows that a simple combination of blood biomarkers and biological sex can identify these patients with remarkable accuracy even before cardiac catheterization,” said Florian A. Wenzl, co-first author of the study at the Center for Molecular Cardiology at the University of Zurich and the Radcliffe Department of Medicine at the University of Oxford.

“The BioTAK score is not a substitute for cardiac catheterization when it is medically necessary. However, it could help guide diagnostic procedures more effectively and avoid unnecessary invasive tests in selected patients,” said Christian Templin, co-last author and director of the Department of Internal Medicine B at the University Medical Center Greifswald and founder of the InterTAK Registry. “Our goal is to identify patients with Takotsubo syndrome earlier and more reliably in the future, while also gaining a better understanding of the underlying disease mechanisms.” 

Related Links
University of Zurich
University Medical Center Greifswald


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.